trial summary · NCT07169799
Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE)
Evaluating the Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE)
Trial record from the TrialBase DB dataset, status RECRUITING, condition Gastric Antral Vascular Ectasia, sponsored by Mayo Clinic. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
The purpose of this study is to evaluate the impact of cryotherapy spray treatment for eradication of gastric antral vascular ectasia by measuring the change in hemoglobin levels and transfusion requirements in the first 6 months of cryotherapy treatment compared to the previous 6 months
Source record: https://clinicaltrials.gov/study/NCT07169799
Facts
| registry id | NCT07169799 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | not reported |
| study type | INTERVENTIONAL |
| lead condition | Gastric Antral Vascular Ectasia |
| sponsor | Mayo Clinic |
| sponsor class | OTHER |
| enrollment | 50 |
| start date | 2026-12-22 |
| primary completion | 2028-09-30 |
| completion | 2028-12-31 |
| results posted | not reported |
Conditions
- Gastric Antral Vascular Ectasia
Interventions
- trūFreeze® Spray Cryotherapy System (STERIS Endoscopy)
Countries
- United States
Intervention types: OTHER
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.